Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Sidley says it published a China biotech licensing guide on Treasury’s proposal
Sidley said it published a life sciences analysis of Treasury’s proposed outbound investment restrictions and their implications for China licensing transactions. The firm said its update examined how biotechnology activities, ownership structures and deal terms could bring investments within the proposed framework, which had not yet become final.
Key points
- Sidley discussed the proposed treatment of pharmaceutical compounds and related biotechnology activities.Sidley
- The firm examined licensing arrangements that involve equity investments.Sidley
- Sidley addressed the application of the proposal to joint ventures.Sidley
- The firm said comments were due on December 7, 2026.Sidley